Sglt 2i CKD Farxiga denied as not FDA-approved for this use by Cigna?

Cigna's specific coverage criteria for sglt2i ckd farxiga are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Cigna Issued a "Not FDA-Approved" Denial for Farxiga in CKD — and How to Appeal

A "not FDA-approved" denial for dapagliflozin (Farxiga) in the context of chronic kidney disease is directly contradicted by the public FDA record. Dapagliflozin carries a specific FDA approval for use in adults with CKD to reduce the risk of sustained decline in kidney function and kidney failure. This type of denial is most commonly the result of a plan system applying a stale or misdirected coverage policy — one that was drafted before the CKD indication was added to the label, or one that was intended for a different drug or indication.

This is one of the most rebuttable denial types, because the FDA's approval record is public, dated, and authoritative. You do not need clinical expertise to make the primary argument — you need the FDA-approved label.

### Why This Denial Is Frequently Overturned

Independent external reviewers apply objective criteria. When a prescriber submits the FDA-approved label for dapagliflozin showing the CKD indication alongside a plan coverage policy that incorrectly states the drug is not FDA-approved for the condition, the reviewer has a clear factual basis to overturn. The appeal also creates a formal record that the plan's policy is outdated — useful if further action is needed.

### Federal Appeal Framework

• Internal appeal (ACA / ERISA §503): File within the deadline on the denial letter. Request a clinical reviewer with nephrology expertise. You are entitled to a reviewer not involved in the original denial.
• External review (ACA §2719): If internally denied, file for independent external review within approximately four months of the final internal denial. The decision is binding on Cigna.
• Expedited option: If clinical urgency exists, both stages may be expedited — typically 72-hour decisions.
• State insurance commissioner: If the plan's policy is demonstrably inconsistent with the FDA record, a concurrent complaint to your state insurance regulator can accelerate the process.

### Concrete Appeal Steps and Timeline

1. Download the current FDA-approved prescribing information for Farxiga from the FDA's official website (FDA.gov or DailyMed). Print the "Indications and Usage" section. 2. Obtain the Cigna coverage policy that was applied. Record its effective and revision dates. 3. Compare the two documents: if the policy predates the FDA's addition of the CKD indication, document that date gap explicitly. 4. Ask your prescriber and/or nephrologist to write a letter confirming: the FDA-approved indication for dapagliflozin in CKD, the patient's diagnosis meeting that indication, and the factual error in Cigna's denial basis. 5. File the internal appeal with the FDA label, the dated Cigna policy, and the prescriber letter as exhibits. 6. File for external review immediately upon internal denial.

### Documentation to Gather

• FDA prescribing label for Farxiga (current version): CKD indication highlighted.
• Cigna's coverage policy and its effective date: To establish the policy's age relative to the FDA approval.
• CKD diagnosis records: Chart notes confirming the diagnosis.
• Prescriber letter: States the FDA-approved indication, identifies the factual error in the denial, and documents clinical necessity.

### Criteria-Mapping Structure

The appeal letter should lead with the factual rebuttal: quote Cigna's denial language, then quote the relevant section of the FDA label verbatim. Follow with the prescriber's confirmation. This structure makes the error impossible to overlook and gives the internal reviewer a clear path to overturn without needing to exercise clinical judgment.